ADCC Antibody Applications

  • click to rate

    In some follow-up studies of antibodies that have been on the market for many years, such as rituximab (CD20) and trastuzumab (HER2), it was found that the ADCC effect of these antibodies is an important mechanism for killing tumors in vivo. Due to the scarcity of existing targets and the difficulty in discovering new targets for immunotherapy, some scientists have turned their attention to ADCC antibody applications to develop biologically better drugs. Therefore, how to cultivate or extract existing target antibodies is currently a hot topic in this field.

    ADCC-enhanced antibody development and ADCC assay to exert stronger tumor killing function is two important part of the development of biologically better drugs. Up to now, two antibody drugs that enhance ADCC effect, Roche's CD20 antibody Gazyva and Concord's fermented Kyte CCR4 antibody Poteligeo, have been approved by the FDA.